* Aclaris Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2024
* The Wayne Pennsylvania-based company is expected to report a 23.3% decrease in revenue to $7.119 million from $9.28 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Aclaris Therapeutics Inc is for a loss of 1 cent per share.
* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $1.60, below its last closing price of $1.81.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.20 -0.20 -0.15 Beat 26.6
Mar. 31 2024 -0.26 -0.29 -0.24 Beat 16
Dec. 31 2023 -0.33 -0.34 -0.02 Beat 94.2
Sep. 30 2023 -0.47 -0.48 -0.41 Beat 14.6
Jun. -0.44 -0.45 -0.42 Beat 6.7
30 2023
Mar. 31 2023 -0.43 -0.44 -0.40 Beat 8.6
Dec. 31 2022 -0.45 -0.45 -0.41 Beat 8
Sep. 30 2022 -0.39 -0.40 -0.30 Beat 24.2
This summary was machine generated November 1 at 14:57 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments